FR2986071A1 - METHOD FOR PROGNOSING, IN VITRO, IN A BLOOD SAMPLE, THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE - Google Patents

METHOD FOR PROGNOSING, IN VITRO, IN A BLOOD SAMPLE, THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE Download PDF

Info

Publication number
FR2986071A1
FR2986071A1 FR1250646A FR1250646A FR2986071A1 FR 2986071 A1 FR2986071 A1 FR 2986071A1 FR 1250646 A FR1250646 A FR 1250646A FR 1250646 A FR1250646 A FR 1250646A FR 2986071 A1 FR2986071 A1 FR 2986071A1
Authority
FR
France
Prior art keywords
severe dengue
patient
prognosing
vitro
probability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR1250646A
Other languages
French (fr)
Other versions
FR2986071B1 (en
Inventor
Frederic Bedin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Biomerieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1250646A priority Critical patent/FR2986071B1/en
Application filed by Biomerieux SA filed Critical Biomerieux SA
Priority to US14/364,456 priority patent/US9863948B2/en
Priority to PCT/FR2013/050143 priority patent/WO2013110894A1/en
Priority to BR112014017952-2A priority patent/BR112014017952B1/en
Priority to PT137041950T priority patent/PT2807486T/en
Priority to ES13704195.0T priority patent/ES2627940T3/en
Priority to EP13704195.0A priority patent/EP2807486B1/en
Publication of FR2986071A1 publication Critical patent/FR2986071A1/en
Application granted granted Critical
Publication of FR2986071B1 publication Critical patent/FR2986071B1/en
Priority to US15/852,528 priority patent/US10823732B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention a pour objet un procédé pour pronostiquer, in vitro, dans un échantillon sanguin, la probabilité pour un patient d'évoluer vers une dengue sévère, dans lequel : a) on détermine la quantité d'au moins un marqueur et b) on la compare avec une quantité de référence obtenue à partir d'un groupe d'individus qui ont été diagnostiqués comme étant atteints d'une dengue non sévère, et si la quantité déterminée dans l'étape a) est supérieure à la quantité de référence établie dans l'étape b), on pronostique que le patient va évoluer vers une dengue sévère, ainsi que l'utilisation de marqueur (s) de pronostic et un kit de pronostic de l'évolution vers une dengue sévère.The present invention relates to a method for prognosing, in vitro, in a blood sample, the probability of a patient progressing to a severe dengue, wherein: a) the quantity of at least one marker is determined and b) it is compared with a reference amount obtained from a group of individuals who have been diagnosed with non-severe dengue, and if the quantity determined in step a) is greater than the reference amount established in step b), it is predicted that the patient will progress to severe dengue, as well as the use of prognostic marker (s) and a prognosis kit of progression to severe dengue fever.

FR1250646A 2012-01-24 2012-01-24 METHOD FOR PROGNOSING, IN VITRO, IN A BLOOD SAMPLE, THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE Active FR2986071B1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR1250646A FR2986071B1 (en) 2012-01-24 2012-01-24 METHOD FOR PROGNOSING, IN VITRO, IN A BLOOD SAMPLE, THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE
PCT/FR2013/050143 WO2013110894A1 (en) 2012-01-24 2013-01-23 Method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample
BR112014017952-2A BR112014017952B1 (en) 2012-01-24 2013-01-23 PROCESS FOR PROOGNIZING IN VITRO IN A BLOOD SAMPLE THE PROBABILITY FOR A PATIENT TO EVOLVE INTO SEVERE DENGUE
PT137041950T PT2807486T (en) 2012-01-24 2013-01-23 Method for the in vitro prediction of the probability of a patient developing severe dengue, based on blood sample
US14/364,456 US9863948B2 (en) 2012-01-24 2013-01-23 Method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample
ES13704195.0T ES2627940T3 (en) 2012-01-24 2013-01-23 Procedure to predict, in vitro, in a blood sample the probability for a patient to evolve into severe dengue
EP13704195.0A EP2807486B1 (en) 2012-01-24 2013-01-23 Method for the in vitro prediction of the probability of a patient developing severe dengue, based on blood sample
US15/852,528 US10823732B2 (en) 2012-01-24 2017-12-22 Method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1250646A FR2986071B1 (en) 2012-01-24 2012-01-24 METHOD FOR PROGNOSING, IN VITRO, IN A BLOOD SAMPLE, THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE

Publications (2)

Publication Number Publication Date
FR2986071A1 true FR2986071A1 (en) 2013-07-26
FR2986071B1 FR2986071B1 (en) 2014-02-28

Family

ID=46826603

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1250646A Active FR2986071B1 (en) 2012-01-24 2012-01-24 METHOD FOR PROGNOSING, IN VITRO, IN A BLOOD SAMPLE, THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE

Country Status (7)

Country Link
US (2) US9863948B2 (en)
EP (1) EP2807486B1 (en)
BR (1) BR112014017952B1 (en)
ES (1) ES2627940T3 (en)
FR (1) FR2986071B1 (en)
PT (1) PT2807486T (en)
WO (1) WO2013110894A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3017713B1 (en) * 2014-02-18 2018-01-12 Biomerieux METHOD AND KIT FOR DETERMINING THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE
FR3017714A1 (en) 2014-02-18 2015-08-21 Biomerieux Sa METHOD AND KIT FOR DETERMINING THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE
MY168633A (en) * 2014-06-13 2018-11-14 Univ Malaya Biomarker for severe dengue

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145810A2 (en) * 2008-01-08 2009-12-03 University Of Massachusetts Medical School St2-based dengue fever diagnostic
WO2011092219A1 (en) * 2010-01-26 2011-08-04 University College Dublin, National University Of Ireland Biomarkers of cardiovascular disease including lrg

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715654B2 (en) * 2008-10-02 2014-05-06 Celtaxsys, Inc. Methods of modulating the negative chemotaxis of immune cells
BR112012025593A2 (en) * 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings circulating biomarkers for disease
WO2012178196A2 (en) * 2011-06-24 2012-12-27 La Jolla Institute For Allergy And Immunology Protection against dengue virus and prevention of severe dengue disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145810A2 (en) * 2008-01-08 2009-12-03 University Of Massachusetts Medical School St2-based dengue fever diagnostic
WO2011092219A1 (en) * 2010-01-26 2011-08-04 University College Dublin, National University Of Ireland Biomarkers of cardiovascular disease including lrg

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHAIYARATANA WATHANEE ET AL: "Serum ferritin levels in children with dengue infection", SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, PROJECT OD SEAMEO, BANGKOK, vol. 39, no. 5, 1 September 2008 (2008-09-01), pages 832 - 836, XP009165364, ISSN: 0125-1562 *
LIDIANE M ALBUQUERQUE ET AL: "Two-Dimensional Difference Gel Electrophoresis (DiGE) Analysis of Plasmas from Dengue Fever Patients", JOURNAL OF PROTEOME RESEARCH, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 8, no. 12, 4 December 2009 (2009-12-04), pages 5431 - 5439, XP008146903, ISSN: 1535-3907, [retrieved on 20091021], DOI: 10.1021/PR900236F *
PAWITAN JEANNE A: "Dengue virus infection: predictors for severe dengue.", ACTA MEDICA INDONESIANA APR 2011, vol. 43, no. 2, April 2011 (2011-04-01), pages 129 - 135, XP002688549, ISSN: 0125-9326 *
SRIKIATKHACHORN ANON ET AL: "Markers of dengue disease severity.", CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY 2010, vol. 338, 2010, pages 67 - 82, XP009165400, ISSN: 0070-217X *
WEIVODA S ET AL: "ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 336, no. 1, 20 July 2008 (2008-07-20), pages 22 - 29, XP022682287, ISSN: 0022-1759, [retrieved on 20080404], DOI: 10.1016/J.JIM.2008.03.004 *

Also Published As

Publication number Publication date
US10823732B2 (en) 2020-11-03
US20150126386A1 (en) 2015-05-07
BR112014017952A8 (en) 2017-07-11
US20180120316A1 (en) 2018-05-03
FR2986071B1 (en) 2014-02-28
BR112014017952B1 (en) 2022-05-24
WO2013110894A1 (en) 2013-08-01
EP2807486A1 (en) 2014-12-03
EP2807486B1 (en) 2017-03-15
US9863948B2 (en) 2018-01-09
BR112014017952A2 (en) 2017-06-20
PT2807486T (en) 2017-06-22
ES2627940T3 (en) 2017-08-01

Similar Documents

Publication Publication Date Title
MX2018004400A (en) Methods and systems for improving skin condition.
MX2018009304A (en) Diagnostic and prognostic methods for cardiovascular diseases and events.
EA201591411A1 (en) SYSTEMS AND METHODS TO SUPPORT CLINICAL DECISIONS
WO2012021795A3 (en) Pancreatic cancer biomarkers and uses thereof
EP3744859A3 (en) Microrna biomarker for the diagnosis of gastric cancer
MA39570B1 (en) Multifilament polyester fibers
ATE548467T1 (en) METHOD FOR IDENTIFYING BIOMARKERS USEFUL IN DIAGNOSING BIOLOGICAL CONDITIONS
MA34966B1 (en) FGFR AND ITS LIGANDS USED AS BIOMARKERS OF BREAST CANCER IN POSITIVE RH SUBJECTS
BR112012025517A2 (en) ____________________________________________________________ antibody recognizing human leukemia inhibitor (lif) inhibitor and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201390638A8 (en) ENTRANCE AND IDENTIFICATION OF FETAL CELLS IN MATERNAL BLOOD AND LIGANDS FOR SUCH APPLICATION
AR087445A1 (en) METHOD FOR ESTABLISHING THE RISK OF CARDIOVASCULAR DISEASE
FR2986071A1 (en) METHOD FOR PROGNOSING, IN VITRO, IN A BLOOD SAMPLE, THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE
ATE500503T1 (en) CD86 AND CD80 RECEPTOR COMPETITION TESTS
WO2015095862A3 (en) Microrna biomarkers for ovarian cancer
WO2020059997A8 (en) Oxidation-reduction polymer including transition metal complex, and electrochemical biosensor using same
NZ601648A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010149810A3 (en) In vitro method for the prognosis or prediction of the response in patients with rheumatoid arthritis treated with agents that recognize the cd20 membrane receptor in b lymphocytes
EP3492607A3 (en) Urinary mirnas for the in vitro diagnosis of bladder cancer
ATE528651T1 (en) DIAGNOSTIC METHODS FOR PULMONARY ARTERIAL HYPERTENSION
BR112014008311A2 (en) prognostic method for diabetes
CR20130018A (en) METHOD FOR DIAGNOSING A RESPONSE TO TREATMENT IN SUBJECTS WITH MULTIPLE SCLEROSIS
FR2992148B1 (en) COMPOSITION COMPRISING ARTHROPODS AND EGGS OF ASTIGMATES
MX2013012648A (en) Method for determining clinically relevant hypoxia in cancer.
MA35216B1 (en) Probes and primers for detecting bcr-abl gene in duplex reaction

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13